Ciodaro Francesco, Mannella Valentina Katia, Cammaroto Giovanni, Bonanno Lilla, Galletti Francesco, Galletti Bruno
Department of Otorhinolaryngology, University of Messina, Via Consolare Valeria 1, 98100, Messina, Italy.
Eur Arch Otorhinolaryngol. 2015 Oct;272(10):2825-30. doi: 10.1007/s00405-014-3304-z. Epub 2014 Sep 28.
The objective of our work is to evaluate recovery induced by gabapentin alone and in association with intradermal infiltration of lidocaine in patients affected by moderate/severe tinnitus. Seventy-two patients suffering from moderate/severe unilateral non-pulsatile subjective tinnitus were enrolled. Severity and behaviour of tinnitus were assessed by Tinnitus handicap Index (THI) on the 8th, 22nd and 36th days from onset of therapy, and on the 3rd and 6th month after the end of therapy in patients treated with oral gabapentin (Group I), oral gabapentin and intradermal injection of lidocaine (Group II), and placebo (Group III) Significant differences in THI scores from the 8th day of therapy to the 22nd (p < 0.0001) and from the 22nd day to the 36th (p = 0.0002 and p = 0.0004, respectively) were found in Group I and Group II. In Group II, another relevant decrease of THI scores from the 36th day of therapy to 3 months from the end of treatment (p = 0.0004) was found. A significant difference in THI scores between Group I and Group II was found after 8 days of treatment (p = 0.05) with a more relevant decrease registered in Group II; significant differences were also found in THI scores between Group I and Group III after 8 days of treatment (p = 0.01), with a more relevant decrease registered in Group III; significant differences in THI scores between Group II and Group III were found after 36 days of treatment (p = 0.009), 3 and 6 months after the end of therapy (p = 0.005 and p = 0.007, respectively), with a more relevant decrease registered in Group II. In conclusion, the use of gabapentin associated to lidocaine seems to be superior to placebo and gabapentin in relieving tinnitus.
我们这项工作的目的是评估加巴喷丁单独使用以及与利多卡因皮内浸润联合使用对中重度耳鸣患者耳鸣恢复情况的影响。招募了72名患有中重度单侧非搏动性主观性耳鸣的患者。通过耳鸣残障指数（THI）在治疗开始后的第8天、第22天和第36天，以及口服加巴喷丁治疗的患者（第一组）、口服加巴喷丁和利多卡因皮内注射治疗的患者（第二组）和安慰剂治疗的患者（第三组）在治疗结束后的第3个月和第6个月评估耳鸣的严重程度和特征。在第一组和第二组中，从治疗第8天到第22天（p < 0.0001）以及从第22天到第36天（分别为p = 0.0002和p = 0.0004），THI评分存在显著差异。在第二组中，从治疗第36天到治疗结束后3个月，THI评分又有显著下降（p = 0.0004）。治疗8天后，第一组和第二组的THI评分存在显著差异（p = 0.05），第二组下降更为明显；治疗8天后，第一组和第三组的THI评分也存在显著差异（p = 0.01），第三组下降更为明显；治疗36天后、治疗结束后3个月和6个月，第二组和第三组的THI评分存在显著差异（分别为p = 0.009、p = 0.005和p = 0.007），第二组下降更为明显。总之，加巴喷丁与利多卡因联合使用在缓解耳鸣方面似乎优于安慰剂和加巴喷丁单独使用。
